Oncology

Human cells
#Cancer research #Immune response #Immunotherapy #Oncology

The Achilles’ heel of cancer

Listen to this article on the DDW Podcast: Genoscience Pharma’s Philippe Halfon and Eric Raymond share their expertise on targeting the recycling of unsustainable production of palmitoylated cancer-associated proteins. Cancer relies on palmitoylation for progression Palmitoylation is a global post-translational lipid modification, that controls… Read More

#Cancer Research #Exclusive Content

Kaposi Sarcoma
#Cancer research #Immunotherapy #Oncology #Proteomics #The Institute of Cancer Research

Sarcoma ‘Rosetta stone’ could bring new era of personalisation

Scientists have unveiled the first and largest encyclopaedia of protein alterations in soft tissue sarcomas – opening the door to a new era of understanding and treatment for this group of rare cancers. The pioneering encyclopaedia, or ‘Rosetta Stone’, of sarcoma biology compiles a wealth of… Read More

#Cancer Research #Editor's Choice #News

T cells
#Cancer research #Icahn School of Medicine #Immunotherapy #Melanoma #mRNA #Oncology #Solid tumours

RNA strategy activates dendritic cells and eradicates melanoma tumours

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The findings, which suggest that the approach has the potential to be effective against tumours… Read More

#Cancer Research #Editor's Choice #News

#Cancer drug targets #Cancer research #Cancer vaccine #Immunotherapy #Lung cancer #Oncology

World Lung Cancer Day: Five drug discovery breakthroughs

This World Lung Cancer Day, DDW’s Diana Spencer takes a look at five 2023 discoveries that could transform the treatment of lung cancer in the near future. Allogeneic cell vaccines In July 2023, Lineage Cell Therapeutics and Cancer Research UK announced encouraging primary and secondary endpoint… Read More

#Cancer Research #News #Trending News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

New podcast episode: DDW Highlights 31 July 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  To coincide with the publication of the DDW eBook ‘Antibody discovery:… Read More

#News

Cancer research in laboratory
#Cancer research #Oncology #Phase II trial #Promontory Therapeutics #Prostate cancer

Promontory Therapeutics expands Phase II mCRPC trial

Promontory Therapeutics has treated its first patients in France as part of the ongoing Phase II clinical trial of PT-112 in patients with late-stage metastatic castration-resistant prostate cancer (mCRPC). The Phase II proof-of-concept study has the objective of characterising the benefit-risk ratio and selecting the optimal… Read More

#Cancer Research #News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

This week in drug discovery (24-28 July)  

News round-up for 24-28 July by DDW Digital Content Editor Diana Spencer. To coincide with the publication of the DDW eBook ‘Antibody discovery: Breakthroughs accelerating therapeutic antibodies’, our news highlights this week all focus on antibodies, particularly the recommendation by the EU’s CHMP… Read More

#News

T cells attacking cancer
#allogeneic cell therapies #Cancer research #Cancer Research UK #Lineage Cell Therapeutics #Lung cancer #Oncology

Topline results support allogeneic dendritic cell vaccine in lung cancer

Lineage Cell Therapeutics and Cancer Research UK have announced encouraging primary and secondary endpoint results from their clinical study of VAC2 in advanced non-small cell lung cancer (NSCLC). Five of eight patients treated (62.5%) had a best response of immune-related stable disease, and three (37.5%) demonstrated… Read More

#Cancer Research #News

Click chemistry
#Cancer research #Click chemistry #Immunotherapy #Oncology #Stanford University #University College London

Novel anti-cancer therapy created using click chemistry

A potent anti-cancer therapy has been created using Nobel prize-winning “click chemistry”, in a new study by University College London (UCL) and Stanford University researchers. The study, published in Nature Chemistry, opens up new possibilities for how cancer immunotherapies might be built in… Read More

#Cancer Research #News #Trending News

Scientist in laboratory
#Cancer research #Crescendo Biologics #Financing #Oncology #Phase I trial #Solid tumours

Crescendo secures $32M to expand Phase Ib trial in solid tumours

Immuno-oncology company Crescendo Biologics has revealed plans to augment the ongoing Phase Ib clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major existing shareholders, including Sofinnova… Read More

#Cancer Research #News

IgE antibodies
#Antibody #Cancer research #Cancer Research UK #Epsilogen #King's College London #Oncology #Phase I trial

New class of antibody cancer drug shows promise

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The Phase I clinical trial, sponsored and managed by Cancer Research UK’s Centre for Drug Development, tested whether… Read More

#Cancer Research #News

Human antibodies
#Cancer research #Guide #Immuno-oncology #Immunotherapy #Immutep #Oncology

Immunotherapy is here to stay

Listen to this article on the DDW Podcast: DDW’s Megan Thomas spoke with Frédéric Triebel, the French immunologist/oncologist who is best known for his 1990 discovery of the LAG-3 immune control mechanism. Triebel shares insights from his career, expands on his experience with the company he… Read More

#Cancer Research #Exclusive Content

Leukaemia
#Blood cancer #Cancer research #CHMP #EMA #European Commission #Jazz Pharmaceuticals #Leukaemia #Oncology

EU positive opinion for acute lymphoblastic leukaemia drug

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorisation of JZP458 (a recombinant Erwinia asparaginase or crisantaspase). It has been recommended for use as a component of a multi-agent chemotherapeutic… Read More

#News #Regulatory

Bispecific antibodies
#AbbVie #Bispecific Antibodies #Cancer research #CHMP #EMA #Genmab #Haematology #Oncology

Bispecific antibody a “promising treatment option” for DLBCL

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of conditional marketing authorisation for epcoritamab (Tepkinly) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines… Read More

#News #Regulatory

Antibodies
#Antibody-based therapeutics #Cancer research #Cancer Research Horizons #Oncology #Synthetic libraries #Twist Bioscience

Partnership could enhance antibody discovery for cancer research

Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. Under the terms of the agreement, Cancer Research Horizons will license Twist’s ‘Library of Libraries’, a collection of synthesised antibody libraries designed based on naturally occurring sequences that… Read More

#Cancer Research #News